Financial Statements

Taro Pharmaceutical Industries Ltd. (TARO)

$37.77

+0.61 (+1.64%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands

Retained Earning Schedule

Year 2021 2020 2019 2018 2017
Retained Earnings (Previous Year) 2,7252,4812,6622,451-
Net Income -387244282211456
Stock Dividends -2,339-37-1,995
Dividend Paid ---500--
Retained Earnings -2,7252,4812,6622,451

PPE Schedule

Year 2021 2020 2019 2018 2017
Gross PPE 212206194180-
Annual Depreciation 11344343216
Capital Expenditure -17-28-31-30-36
Net PPE 206212206194180

Intangible and Goodwill Schedule

Year 2021 2020 2019 2018 2017
Intangible and Goodwill (Previous Year) -7777
New Purchases -287-1,141-1,166-1,222-1,133
Intangible and Goodwill 7777-

Taro Pharmaceutical Industries Ltd. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Taro Pharmaceutical Industries Ltd. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.